FDA's Shift to One Pivotal Trial for Drug Approval: Regulatory Strategy Implications for Sponsors

In a move that could reshape modern drug development, on February 19, 2026, FDA formally confirmed that one adequate and well-controlled pivotal trial may now serve as the default basis for drug...